ARCHIVES

Bosutinib Vs. Imatinib Study Didn’t Meet Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 33 No. 12 | December 31, 2010

Download PDF Visit The Full Archive

Related Articles

First analysis From Profiles Reveal New Data On Centers

November 18, 1977

Dana-Farber Correction Plan Sent To State; Pharmacy Chief Resigns

June 9, 1995

Risk of Relapse Continues After Five Years of Therapy

August 29, 2008

Perjeta Neoadjuvant Therapy Granted Accelerated Approval In HER2 Breast Cancer

October 25, 2013

Von Eschenbach says he will continue as NCI director and give both jobs “100 percent.”

September 30, 2005

In Brief: NCAB Schedules Full Day Of AIDS Discussion; PBS To Show Documentary On Tobacco Issues

November 6, 1987